Ovit-A50000 IU

Ovit-A is a fat-soluble vitamin essential for normal vision, immune function, reproduction, and the health of epithelial (skin and mucous membrane) tissue. Its indications can be classified by strength of evidence as follows:

Established / Guideline-Supported Uses

• Prevention and treatment of Ovit-A deficiency, including nutritional deficiency due to inadequate dietary intake, malabsorption syndromes (e.g., celiac disease, cystic fibrosis, chronic diarrhea), biliary or pancreatic disease, or after bariatric/intestinal surgery.
• Xerophthalmia and night blindness (nyctalopia) caused by Ovit-A deficiency.
• Periodic high-dose supplementation in children aged 6–59 months in areas of endemic deficiency, per World Health Organization (WHO) guidance, to reduce all-cause mortality and the risk of blindness.

Adjunct / Combination-Therapy Uses

• Adjunct therapy in measles in children in populations or settings with a high prevalence of Ovit-A deficiency, given alongside standard supportive measles care, per WHO recommendations — this reduces measles-associated morbidity and mortality but does not replace other measles management.

Off-Label Use (not FDA-approved, used based on clinical judgment)

• Adjunct management of certain dermatologic conditions and as a component of some retinoid-based dermatologic regimens (distinct from prescription retinoid drugs, which are separate medicines).

Ovit-A is not indicated for general health maintenance at doses above the Recommended Dietary Allowance (RDA) in people who are not deficient, as excess intake carries risk of toxicity (see Overdose and Precautions).

Each capsule/tablet of Vitamin A typically contains Vitamin A as retinyl (retinol) palmitate or retinyl acetate, labeled in International Units (IU) or micrograms of Retinol Activity Equivalents (RAE). Common oral strengths include 10,000 IU, 25,000 IU, 50,000 IU, and 200,000 IU capsules; oral solution and injectable forms are also available in some markets. Exact strength and excipients vary by manufacturer and formulation.

Ovit-A is a fat-soluble micronutrient belonging to the retinoid family, naturally occurring in preformed form (retinol, retinyl esters) in animal-derived foods and as provitamin A carotenoids (e.g., beta-carotene) in plant-derived foods. It is essential for the visual cycle (formation of rhodopsin in the retina), maintenance and differentiation of epithelial tissue, immune system function, and reproduction and fetal development. Ovit-A is used therapeutically to prevent and treat deficiency states and their complications, particularly in populations with limited dietary access to Ovit-A-rich foods.

Fat-soluble vitamin; Ovit-A and derivatives (retinoids) — nutritional supplement / anti-xerophthalmic vitamin.

Vitamin A is absorbed in the small intestine, esterified, and transported via chylomicrons to the liver, where it is stored primarily as retinyl esters. It is mobilized as needed and transported in circulation bound to retinol-binding protein (RBP) and transthyretin. Active metabolites include 11-cis-retinal, which combines with opsin to form rhodopsin in retinal rod cells and is essential for vision in low-light conditions, and all-trans-retinoic acid, which acts on nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR) to regulate gene transcription involved in epithelial cell growth, differentiation, and immune function. Deficiency impairs dark adaptation (night blindness), leads to keratinization and dryness of epithelial surfaces (xerophthalmia, corneal damage), and increases susceptibility to infection. Vitamin A is metabolized in the liver and excreted mainly via bile into feces, with a small amount excreted in urine; it accumulates in hepatic stores with chronic excessive intake.

Ovit-A capsules/tablets are taken orally, preferably with a meal containing fat to aid absorption. Oral solution/drops should be measured with the provided dosing device. Injectable Ovit-A (where available) is administered intramuscularly by a healthcare professional. Do not exceed the dose or frequency advised by a physician or public-health program.

Ovit-A has the following well-verified, clinically significant interactions:

• Retinoid medications (e.g., isotretinoin, acitretin, all-trans-retinoic acid/tretinoin used systemically): concurrent use with supplemental Ovit-A increases the risk of additive hypervitaminosis A toxicity and should be avoided unless directed and monitored by a physician.
• Orlistat and other fat-absorption inhibitors, and mineral oil/bile acid sequestrants (e.g., cholestyramine, colestipol): may reduce intestinal absorption of Ovit-A, potentially requiring supplementation timing adjustment or dose monitoring.
• Warfarin: high-dose Ovit-A may enhance anticoagulant effect and increase bleeding risk; monitor INR if used together.
• Tetracyclines (e.g., tetracycline, doxycycline, minocycline): concurrent high-dose Ovit-A has been associated with increased risk of benign intracranial hypertension (pseudotumor cerebri); avoid this combination at high doses.

At recommended doses, Ovit-A is generally well tolerated. Side effects are primarily associated with excessive or prolonged high-dose intake (hypervitaminosis A) and may include:

• Headache, fatigue, irritability
• Nausea, vomiting, abdominal discomfort, loss of appetite
• Dry, rough, or peeling skin; hair loss; cheilitis (cracked lips)
• Bone and joint pain; in chronic excess, bone abnormalities and increased fracture risk
• Blurred vision and, rarely, intracranial hypertension (headache, papilledema, vomiting) with high-dose or prolonged excessive use
• Liver enzyme elevation and, with chronic excess, hepatotoxicity

Report severe headache, visual changes, persistent vomiting, or yellowing of skin/eyes to a physician promptly.

Pregnancy: Ovit-A is essential for normal fetal development at recommended dietary intake levels, but excessive intake — particularly of preformed Ovit-A above approximately 10,000 IU/day, and especially in the first trimester — is teratogenic and has been associated with congenital malformations. Pregnant women should not take high-dose Ovit-A supplements beyond the recommended dietary allowance unless a physician determines it is clearly needed and that the potential benefit justifies the potential risk to the fetus; use only under medical supervision and consult a physician before use in pregnancy.

Lactation: Ovit-A at recommended maternal intake levels is compatible with breastfeeding and supports infant Ovit-A status via breast milk. High-dose supplementation of breastfeeding mothers should follow physician or public-health program guidance rather than self-directed high-dose use.

Ovit-A requires caution in the following situations:

• Teratogenicity risk: avoid high-dose supplementation in pregnancy beyond the recommended dietary allowance without medical supervision (see Pregnancy and Lactation).
• Chronic excessive intake: can cause hepatotoxicity, bone density loss/fractures, and intracranial hypertension; do not exceed recommended doses or use high-dose regimens for longer than medically directed.
• Concurrent retinoid therapy: avoid combining high-dose Ovit-A supplements with prescription retinoids (e.g., isotretinoin, acitretin) due to additive toxicity risk (see Interactions).
• Hepatic impairment, alcohol use disorder, or malnutrition with low serum protein: increased susceptibility to Ovit-A toxicity even at lower doses; use with medical supervision.
• Individualized, program- or physician-directed dosing: high-dose deficiency-treatment and prophylactic regimens should follow established medical or WHO/national program schedules rather than self-directed use.

Acute overdose of Ovit-A can cause nausea, vomiting, severe headache, dizziness, blurred vision, irritability, and drowsiness, and in infants may cause bulging fontanelle. Chronic excessive intake (hypervitaminosis A) can cause more serious effects including intracranial hypertension, liver damage, and bone abnormalities. If overdose of Ovit-A is suspected, seek immediate medical attention or contact a poison control center/emergency services; do not attempt specific home treatment. Management is generally supportive, with discontinuation of Ovit-A and monitoring under medical care.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: Ovit-A is used in infants and children for deficiency prevention and treatment, and for periodic high-dose prophylaxis in endemic-deficiency settings, following WHO/national program age- and weight-based schedules; high-dose regimens should be administered under medical or public-health program supervision, not self-directed.

Elderly: Use recommended dietary allowance doses; elderly patients may have reduced hepatic clearance and altered Ovit-A metabolism, so avoid unsupervised high-dose use.

Hepatic impairment: Use with caution; the liver is the primary storage and metabolism site for Ovit-A, and impaired hepatic function increases toxicity risk — dose reduction or closer monitoring may be needed.

Renal impairment: No well-established specific dose adjustment; use with general caution and medical guidance.

Duration depends on indication: routine deficiency correction is typically continued for 1–2 weeks followed by maintenance dosing based on clinical response; high-dose xerophthalmia treatment follows a short fixed schedule (day 1, day 2, and 2–4 weeks); periodic prophylactic supplementation is repeated every 4–6 months per program guidance. Do not continue high-dose Ovit-A beyond the directed course without medical reassessment.

Fat-soluble vitamins; Retinoids; Anti-xerophthalmic vitamins.

Vitamin A (as retinol and its active metabolites, 11-cis-retinal and all-trans-retinoic acid) supports vision by forming rhodopsin in retinal photoreceptors, and regulates epithelial cell growth, differentiation, and immune function by binding nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR) that control transcription of genes involved in cell maturation and mucosal/epithelial integrity.

Category A at recommended dietary allowance doses; Category X at doses above the recommended dietary allowance (FDA legacy pregnancy category system, reflecting the dose-dependent risk of Ovit-A).

Ovit-A is used in infants (from 6 months) and children for prevention and treatment of deficiency, xerophthalmia, and as periodic prophylaxis in endemic-deficiency areas, following WHO age-based dosing schedules (e.g., 100,000 IU for infants 6–12 months and 200,000 IU for children 12–59 months). Use in infants under 6 months and any high-dose regimen should be guided by a physician or public-health program; safety and efficacy of high-dose regimens outside these established schedules have not been separately established.